Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Skye Bioscience Inc.
Headquarters: San Diego, CA, United States of America
Website: https://skyebioscience.com/
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Punit S. Dhillon
Number Of Employees: 16
Enterprise Value: $35,296,698
PE Ratio: -1.92
Exchange/Ticker 1: NASDAQ:SKYE
Exchange/Ticker 2: N/A
Latest Market Cap: $43,364,400
BioCentury | Mar 25, 2025
Management Tracks
Warp Speed veteran Hepburn named EVP of R&D at Panther
Plus: Elicio names Preetam Shah CFO and chief strategy officer, and updates from Halozyme, Newron and Skye
BioCentury | Sep 24, 2024
Politics, Policy & Law
Pediatric PRVs, Biosecure & Novo’s obesity miss: a BioCentury podcast
Misunderstandings on priority review vouchers in Congress. A door closes for Biosecure. Setback for Novo Nordisk
BioCentury | Sep 20, 2024
Product Development
Novo’s Phase II miss in obesity oral amps up pressure on BD
Ph II data from CB1 blocker monlunabant show poor weight loss at 16 weeks, plus neuropsychiatric adverse events
BioCentury | Jun 11, 2024
Product Development
Clinical Report: Shionogi mulls next steps after underwhelming obesity readout
Plus: Bluejay, Vir give HDV updates; Skye’s miss in glaucoma; and more
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | Aug 22, 2023
Deals
Why 5AM and Versant forged a deal to unite two cannabinoid companies
With interest in CB1 on the rise, the longtime backers of Bird Rock saw a path forward by joining its asset with Skye’s
BioCentury | Aug 22, 2023
Regulation
Aug. 21 Quick Takes: Pfizer’s Abrysvo granted maternal indication
Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more
BioCentury | Aug 26, 2019
Company News
Management tracks: Grail, Boehringer, Torque, Bellus and Emerald
Items per page:
1 - 10 of 12